35232-55-4

Basic information

• Product Name: 5-bromo-3-[(5-bromo-3-carboxy-2-hydroxy-phenyl)methyl]-2-hydroxy-benzoic acid
• CAS NO: 35232-55-4
• Molecular Formula: C₁₅H₁₀Br₂O₆
• Molecular Weight: 446.049
• Mol File: 35232-55-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 612.9°Cat760mmHg
• Flash Point: 324.5°C
• Density: 1.999g/cm³
• CAS DataBase Reference: 5-bromo-3-[(5-bromo-3-carboxy-2-hydroxy-phenyl)methyl]-2-hydroxy-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3-[(5-bromo-3-carboxy-2-hydroxy-phenyl)methyl]-2-hydroxy-benzoic acid(35232-55-4)
• EPA Substance Registry System: 5-bromo-3-[(5-bromo-3-carboxy-2-hydroxy-phenyl)methyl]-2-hydroxy-benzoic acid(35232-55-4)

Safety Data

• Hazardous Substances Data: 35232-55-4(Hazardous Substances Data)

Upstream product

• 954108-60-2 5,5'-dibromo-3,3'-dicarbomethoxy-2,2'-dihydroxydiphenylmethane 
• 83174-65-6 Acetic acid 2-(2-acetoxy-5-bromo-benzyl)-4-bromo-phenyl ester 
• 78563-03-8 5,5'-dibromo-2,2'-dihydroxy-diphenyl-methane 
• 50-00-0 formaldehyd 
• 89-55-4 5-bromosalicyclic acid 
• 83143-04-8 1-[3-(3-Acetyl-5-bromo-2-hydroxy-benzyl)-5-bromo-2-hydroxy-phenyl]-ethanone 

Downstream Products

• 129749-42-4 3,3'-dicarbomethoxy-2,2'-dihydroxydiphenylmethane 
• 159500-35-3 5,5'dibromo-2,2'-dimethoxy-3,3'dicarbomethoxybenzophenone 
• 178599-73-0 5,5'-dibromo-3,3'-dicarbomethoxy-2,2'-dimethoxydiphenylmethane 
• 5578-67-6 3,3'-dicarboxy-2,2'-dihydroxydiphenylmethane 

Relevant articles and documents

Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs

A series of compounds containing one or two salicylic acid moieties were synthesized, and their efficacy to inhibit the phosphohydrolase activity of PTP1B examined. Some of the methylenedisalicylic acid derivatives were potent inhibitors of PTP1B. Of those derivatives, 3c exhibited about a 14-fold selectivity against TC-PTP, and this compound was tested in a mouse model for its efficacy to prevent diet-induced obesity. It effectively suppressed the increases in body weight and adipose mass, without any noticeable toxic effect. The compound also prevented increases in the plasma triglyceride, cholesterol, and nonesterified fatty acid concentrations; thus, expanding its therapeutic potential to other related metabolic diseases, such as hyperlipidemia and hypercholesterolemia.

Synthesis and Anti-HIV Activities of Low Molecular Weight Aurintricarboxylic Acid Fragments and Related Compounds

Several compounds corresponding to fragments of the schematic representation of the polymeric structure of aurintricarboxylic acid (ATA) have been prepared and tested for prevention of the cytopathic effect of HIV-1 and HIV-2 in MT-4 cell culture and HIV-